Your browser doesn't support javascript.
loading
Low rates of vaccination among atopic dermatitis, alopecia areata, psoriasis, and psoriatic arthritis patients on biologics.
Hren, M Grace; Khattri, Saakshi.
Afiliación
  • Hren MG; Mount Sinai, Icahn School of Medicine, New York, NY, USA.
  • Khattri S; Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA.
Arch Dermatol Res ; 316(6): 285, 2024 May 25.
Article en En | MEDLINE | ID: mdl-38796548
ABSTRACT
Biologics and Janus kinase (JAK) inhibitors are immunomodulating and immunosuppressing medications utilized to treat atopic dermatitis (AD), psoriasis (PSO), psoriatic arthritis (PsA), and alopecia areata (AA). Special recommendations must be considered when prescribing vaccinations in this population, as the pneumococcal and herpes zoster vaccine are recommended to patients ≥ 19-years-old (rather than ≥ 65-years-old and ≥ 50-years-old as in the general population, respectively), along with a yearly influenza and up to date COVID-19 vaccination. Additionally, TNF-α and JAK-inhibitors may increase the risk of latent Hepatitis B virus (HBV) reactivation among high-risk patients. Prior to prescribing these medications, a quantitative HepB Surface Antibody (HepB SA) test is performed to determine immunity. This study utilized the SlicerDicer function on EPIC Medical Records to search for any patient ≥ 19-years-old prescribed a biologic or JAK inhibitor for AD, PSO, PsA, or AA between 10/2003 and 10/2023 at a large tertiary institution. Vaccination rates among patients on biologics and JAK inhibitors were low, with rates being significantly lower in patients 19-64 years-old, compared to those ≥ 65 years-old for most disease states (p < 0.01). Among AD, PSO/PsA, and AA patients, on average, 9.39% were vaccinated for influenza, 6.76% for herpes zoster, 16.56% for pneumococcal pneumonia, and 63.98% for COVID-19. Only 3.16% of patients were adequately vaccinated for HepB after an abnormal HepB SA test. Here, extremely low rates of vaccination among patients on biologics and JAK inhibitors at our institution were highlighted, emphasizing the imperative need for ensuring vaccination in this group.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / Artritis Psoriásica / Vacunación / Dermatitis Atópica / Alopecia Areata Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arch Dermatol Res Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / Artritis Psoriásica / Vacunación / Dermatitis Atópica / Alopecia Areata Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arch Dermatol Res Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania